ClinicalTrials.gg
RecruitingNCT06893588DILATEUpdated Nov 18, 2026

Registry on NeVa VS for CerebraL VAsospasm ManagemenT in Post SAH PatiEnts

An observational study in Cerebral Vasospasm and Aneurysmal Subarachnoid Hemorrhage (aSAH), sponsored by Vesalio. Recruiting at 16 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Vesalio · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Vasospasm, Intracranial with a site in United States — 6 open to participants now, 7 under way, none of them phase 3. Vasospasm, Intracranial · United States.

Started
2025
the only one that year
Observational
9 of 37
2 open now
Registered
34th of 37
by date
Lead sponsor
2 of 37
Vesalio

Among the 37 studies in Vasospasm, Intracranial with a site in United States, this one is the only one that started in 2025, is one of 9 observational ones, and was the 34th registered.

Vasospasm, Intracranial

82 studies on the registry are indexed under Vasospasm, Intracranial; 15 are open to participants now.

Browse Vasospasm, Intracranial studies →

Open to participants now

6 of the 37 studies in Vasospasm, Intracranial with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Vasospasm, Intracranial studies recruiting now, 5 (45%) set no upper age limit and 2 (18%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Vasospasm, Intracranial with a site in United States, or all of them as a file.
02

Study summary

A multi-center, observational registry study intended to assess the HDE-approved NeVa VS cerebral artery dilation device in patients with symptomatic cerebral vasospasm caused by aneurysmal subarachnoid hemorrhage (aSAH)

03

Conditions studied

  • Cerebral Vasospasm
  • Aneurysmal Subarachnoid Hemorrhage (aSAH)

Keywords

  • vasospasm
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

subjects with cerebral vasospasm

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥22
  2. Symptomatic cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage (aSAH) in the internal carotid artery (ICA), middle cerebral artery (MCA), anterior cerebral artery (ACA), posterior cerebral artery (PCA), or basilar artery (BA)
  3. Vessel dilation procedure was performed with the NeVa VS
  4. Subject or legal representative is able and willing to give within 3 days (72 hours) post-index procedure

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
30 Days
Patient registry
Yes

Groups and cohorts

  • Treatment Group

    Device: NEVA VS

Interventions

  • DeviceNEVA VS

    cerebral artery dilation device

06

What researchers measure

Primary outcomes

  1. Improvement in target vessel diameter following NeVa VS use

    Time frame: Up to 1 hour post procedure

07

Study locations

16 of 16 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Feb 2027, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2025
First posted
Mar 25, 2025
StartActual
Apr 14, 2025
Primary completionEst.
Feb 14, 2027
CompletionEst.
Mar 15, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 1 site. See the sites
Show the site
  • Geisinger · Wilkes-Barre, United StatesContact c•••@geisinger.edu→p•••@geisinger.edu
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Geisinger · Wilkes-Barre, United StatesContact c•••@geisinger.edu→p•••@geisinger.edu
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06893588
Lead sponsor
Vesalio
Responsible party
Sponsor
First posted
Mar 25, 2025
Start date
Apr 14, 2025
Primary completion
Feb 14, 2027 (estimated)
Completion
Mar 15, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Sharon Shachar, Graduate
Contact
sshachar@vesalio.com
2486976616

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion